期刊
NEUROCHEMICAL RESEARCH
卷 42, 期 12, 页码 3362-3371出版社
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11064-017-2382-x
关键词
Parkinson's disease; alpha-Synucleinopathy; alpha-Synuclein; Oligomers; Oligomer hypothesis
资金
- Ministry of Education, Culture, Sports, Science and Technology, Japan [26461266]
- Takeda Science Foundation
- Nagao Memorial Foundation
- Life Science Foundation of Japan
- Grants-in-Aid for Scientific Research [26461266] Funding Source: KAKEN
Lewy bodies and Lewy neurites in the brain constitute the main histopathological features of Parkinson's disease (PD) and dementia with Lewy bodies. They comprise amyloid-like fibrils composed of alpha-synuclein (alpha S), a small protein (similar to 14 kDa). Because the aggregation of alpha S in the brain has been implicated as a critical step in the development of these diseases, the research for disease-modifying drugs has focused on modification of the alpha S aggregation process in the brain. Recent studies using synthetic alpha S peptides, a cell culture model, transgenic mice models, and human samples such as cerebrospinal fluids and the blood of PD patients have suggested that pre-fibrillar forms of alpha S (i.e., oligomers) are more critical than fibrillar forms (such as Lewy bodies) in the pathogenesis of alpha-synucleinopathies. Based on the accumulating evidence that oligomers play a central role in the pathogenesis of PD and other alpha-synucleinopathies (the oligomer hypothesis). This report reviews the recent findings regarding the oligomer hypothesis in the research of alpha-synucleinopathies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据